Chemoresistance of Human Monocyte-Derived Dendritic Cells Is Regulated by IL-17A

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Olsson Åkefeldt, Selma ^a,b,c,d,e,f   Maisse, Carine ^b,c,d,e,f   Belot, Alexandre ^b,c,d,e,f,g   Mazzorana, Marlène ^c,d,e,f,h   Salvatore, Giulia ^{b,c,d,e,f,i,j}   Bissay, Nathalie ^b,c,d,e,f   Jurdic, Pierre ^c,d,e,f,h   Aricò, Maurizio ^j   Rabourdin Combe, Chantal ^d,e,f,k   Henter, Jan Inge ^a   Delprat, Christine ^b,c,d,e,f,l  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Univ Claude Bernard   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f University Lyon i   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h Univ Lyon 1   (France)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

^k INSERM   (France)

^l INSTITUT UNIVERSITAIRE DE FRANCE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; CD14 ANTIGEN; CD163 ANTIGEN; CD206 ANTIGEN; CD40 ANTIGEN; CD68 ANTIGEN; CISPLATIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; LYMPHOCYTE ANTIGEN; MACROPHAGE DERIVED CHEMOKINE; MERCAPTOPURINE; METHOTREXATE; PROTEIN BCL 2; PROTEIN MCL 1; T6 ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOLECULARLY TARGETED THERAPY; MONOCYTE; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DENDRITIC CELLS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-17; MONOCYTES; NF-KAPPA B; PHENOTYPE; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION, GENETIC;

EID: 84874170694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056865     Document Type: Article

References (40)

1. Coussens LM, Werb Z, (2002) Inflammation and cancer. Nature 420: 860-867.
2. Sarra M, Pallone F, Macdonald TT, Monteleone G, (2010) IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 16: 1808-1813.
3. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM, (2009) Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 175: 1167-1177.
4. Korn T, Bettelli E, Oukka M, Kuchroo VK, (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27: 485-517.
5. Gaffen SL, (2009) The role of interleukin-17 in the pathogenesis of rheumatoid arthritis. Curr Rheumatol Rep 11: 365-370.
6. Ely LK, Fischer S, Garcia KC, (2009) Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 10: 1245-1251.
7. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627.
8. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, et al. (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99: 2114-2121.
9. Cheong C, Matos I, Choi JH, Dandamudi DB, Shrestha E, et al. (2010) Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 143: 416-429.
10. Coury F, Annels N, Rivollier A, Olsson S, Santoro A, et al. (2008) Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 14: 81-87.
11. Frenzel A, Grespi F, Chmelewskij W, Villunger A, (2009) Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14: 584-596.
12. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW, (1993) MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A 90: 3516-3520.
13. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, et al. (2005) NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106: 1392-1399.
14. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, et al. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105: 1851-1861.
15. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
16. Rivollier A, Mazzorana M, Tebib J, Piperno M, Aitsiselmi T, et al. (2004) Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104: 4029-4037.
17. D'Souza BN, Edelstein LC, Pegman PM, Smith SM, Loughran ST, et al. (2004) Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. J Virol 78: 1800-1816.
18. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, et al. (2005) High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 113: 730-737.
19. Chang SH, Dong C, (2011) Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 23: 1069-1075.
20. Kriehuber E, Bauer W, Charbonnier AS, Winter D, Amatschek S, et al. (2005) Balance between NF-kappaB and JNK/AP-1 activity controls dendritic cell life and death. Blood 106: 175-183.
21. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, et al. (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365.
22. Karsan A, Yee E, Kaushansky K, Harlan JM, (1996) Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood 87: 3089-3096.
23. Karsan A, Yee E, Harlan JM, (1996) Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1. J Biol Chem 271: 27201-27204.
24. Macaire H, Riquet A, Moncollin V, Biemont-Trescol MC, Duc Dodon M, et al. (2012) Tax Protein-induced Expression of Antiapoptotic Bfl-1 Protein Contributes to Survival of Human T-cell Leukemia Virus Type 1 (HTLV-1)-infected T-cells. J Biol Chem 287: 21357-21370.
25. Olsson A, Norberg M, Okvist A, Derkow K, Choudhury A, et al. (2007) Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia. Br J Cancer 97: 769-777.
26. Chuang PI, Morefield S, Liu CY, Chen S, Harlan JM, et al. (2002) Perturbation of B-cell development in mice overexpressing the Bcl-2 homolog A1. Blood 99: 3350-3359.
27. McDonnell TJ, Korsmeyer SJ, (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349: 254-256.
28. Vogler M, (2012) BCL2A1: the underdog in the BCL2 family. Cell Death Differ 19: 67-74.
29. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, et al. (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1: 13.
30. Biswas SK, Mantovani A, (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889-896.
31. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, et al. (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69: 2000-2009.
32. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr, (1999) NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19: 5923-5929.
33. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N, (2007) Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene 26: 5828-5832.
34. Johnson SA, (2000) Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. Clin Pharmacokinet 39: 5-26.
35. Chao D, Bahl P, Houlbrook S, Hoy L, Harris A, et al. (1999) Human cultured dendritic cells show differential sensitivity to chemotherapy agents as assessed by the MTS assay. Br J Cancer 81: 1280-1284.
36. Binaschi M, Capranico G, De Isabella P, Mariani M, Supino R, et al. (1990) Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int J Cancer 45: 347-352.
37. Yang H, Ganguly A, Cabral F, (2010) Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J Biol Chem 285: 32242-32250.
38. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, et al. (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471: 110-114.
39. Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, et al. (2012) Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 72: 420-429.
40. Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, et al. (2011) Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 121: 4015-4029.